Company ProfilePremium

Artemis Medicare Services Limi

Company Profile Analysis

Tickers: ARTEMISMED.NS, 542919.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Artemis Medicare Services Limi - Company showcase

Year Founded & Workforce

2004

Artemis Medicare Services Limi logo

Artemis Medicare Services Limi Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Artemis Medicare Services Limi Overview

Artemis Medicare Services is a promoter-controlled, mid-sized Indian private hospital operator anchored by a single, high-acuity JCI- and NABH-accredited quaternary-care campus in Gurugram, Delhi-NCR. The flagship generates the overwhelming majority of group revenue and commands one of the highest average revenues per occupied bed (ARPOB) in the NCR market — INR 82,435 in FY26 — driven by a complex case mix (oncology, cardiac sciences, neurosciences, orthopaedics, transplants, robotics) and a large medical-value-travel franchise that contributed roughly 31% of Gurugram revenue in FY26. Backed by the Apollo Tyres promoter family and a World Bank Group (IFC) equity investment, the company is transitioning from a one-hospital story to a multi-site platform: an asset-light operations-and-management model in Raipur (opened July 2026), a 650+ bed managed hospital in South Delhi (VIMHANS, targeted FY29), Mauritius O&M contracts, and brownfield Gurugram towers — with a stated ambition to roughly triple capacity to 2,000+ beds by 2029.


What the company does

AMSL owns and operates multi-specialty tertiary and quaternary care hospitals and allied care formats. Its business is the delivery of in-patient (IP) and out-patient (OP) clinical services — surgery, critical care, diagnostics, interventional procedures, transplants and day-care — billed per episode of care. The company reports a single operating segment, "Healthcare Services," in its audited results (FY26 iXBRL filing).

The company's own description in recent filings and presentations positions Artemis Hospitals as a healthcare venture launched by the Apollo Tyres Group promoters, operating a super-speciality hospital in Gurugram (described in the Q3 FY26 presentation as a ~700-bed facility) and expanding toward ~2,000 beds. Its earlier descriptions (IFC investment press release, April–May 2024) cite 713 beds across the Delhi-NCR footprint, including the 541-bed JCI/NABH-accredited Gurugram hospital, five hospitals under the Artemis Lite and Daffodils brands, and seven Artemis Cardiac Care centres run with Philips.

Business and revenue model

Revenue model elementDescriptionEvidence
Owned-hospital services (core)Fee-for-service billing at the owned Gurugram campus; revenue = occupied bed-days × ARPOB plus OP revenueGurugram contributed INR 1,060 Cr standalone of INR 1,081 Cr consolidated revenue in FY26 (FY26 results)
Operations & Management (O&M) / Medical Services Agreements (MSA)Asset-light (or asset-lighter) contracts where a third party owns land/building and Artemis runs clinical operations under its brand: Raipur (Artemis Shanti), VIMHANS South Delhi, Mauritius (Curepipe, Cascavelle)Raipur O&M/MSA (intimated 14 Nov 2024); VIMHANS MSA (20 Feb 2026); Mauritius O&M (FY24)
Satellite / secondary care formatsArtemis Lite (30–40 bed neighbourhood multi-specialty hospitals), Daffodils by Artemis (mother-and-child)CARE rationale Aug 2023 and Aug 2025
Cardiac network JVArtemis Cardiac Care Pvt Ltd (65% AMSL; Philips partner) operating cardiac centres in Tier 2/3 locationsBRSR FY26; IFC release 2024
Medical value travel (MVT)International patients from 52 countries (Middle East, Africa, CIS); 31.3% of Gurugram net revenue in FY26Q3 FY26 commentary; Q4 FY26 release

There is no meaningful product, subscription or licensing revenue; the mix is essentially 100% service revenue. "Other income" (treasury income on unutilised IFC proceeds) was a material contributor to pre-tax profit in FY25–FY26 and has been declining as funds are deployed into capex (Q3 FY26 and Q1 FY27 presentations).

Customer types and payor mix (Gurugram)

Payor categoryQ4 FY26 share of revenue (%)Q1 FY27 share of revenue (%)Source
International patients3127Q4 FY26 call notes; Q1 FY27 presentation
Insured (TPA/corporate insurance)3133Same
Domestic cash2223Same
Government schemes (CGHS/ECHS/PSU etc.)~16 (implied)17Same (Q4 government share is a residual, derived)

Value-chain position and end-markets

Artemis sits at the high-acuity end of the provider value chain (tertiary/quaternary care), competing for complex referrals (oncology, neurosurgery, cardiac surgery, solid-organ and heart-lung transplant, robotic surgery) rather than primary care volume. Its end-markets are: (a) affluent and insured patients in Gurugram/South Delhi; (b) government-scheme patients (a lower-yield but volume-stabilising cohort); (c) inbound medical travellers; and, newly, (d) Central India (Chhattisgarh) via Raipur.

Independent characterisation

Analytically, AMSL is best understood as a single-asset, high-ARPOB, MVT-heavy hospital that is now spending its balance-sheet capacity (IFC money plus a pending INR 700 Cr raise) to become a three-to-four-asset network. The core asset is mature-to-maturing (occupancy 61–66%, ARPOB growing 7–10% a year), so the next leg of earnings growth depends on execution of new capacity that carries gestation losses (management guided INR 18–20 Cr of losses over the first 15–18 months at Raipur). The model also leans increasingly on O&M/MSA structures, which lower capital intensity but introduce counterparty, contract-tenure and economic-sharing risks that are less transparent than owned-hospital economics.

Strategy

Stated strategic themes (paraphrased from FY26 calls, presentations and releases)

  1. Scale capacity roughly 2.5–3x. Move from ~800 beds to 2,000–2,300 beds by 2029 through a blend of brownfield (Gurugram towers and FAR uplift), greenfield/managed (VIMHANS South Delhi), and O&M/MSA hospitals (Raipur, Mauritius). Earlier presentations cited ~2,000 beds by 2028; the target year has since been stated as 2029.

  2. Deepen high-acuity clinical programmes. Build centres of excellence in transplants (including heart-lung), robotics, neurosciences, oncology and critical care to sustain NCR-leading ARPOB.

  3. Sustain medical value travel at ~30% of flagship revenue while broadening domestic insured volumes.

  4. Asset-light geographic expansion into under-served Tier 2 markets (Raipur first), with VIMHANS providing a second NCR anchor.

  5. Disciplined pricing and mix: FY27 budget assumed ~15% top-line growth, ~15% price hikes and 7–8% annual ARPOB growth.

  6. Capital structure: fund growth from a mix of equity (INR 700 Cr raise; promoters not participating), debt and internal accruals.

Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Raipur O&M/MSAIntimated 14 Nov 2024300+ bed Artemis Shanti Hospital; >50 specialities; 11 CoEsOperational from 9 Jul 2026; gestation losses INR 18–20 Cr over 15–18 months guided
ABTP physiotherapy partnershipFY25Technology-enabled rehabOperational
Gurugram third towerFY26Built capacity ~700 bedsOperational (544 beds open)
Platinum green building certificationQ3 FY26Entitles 15% FAR uplift, enabling 100+ additional bedsAchieved
New departments: Robotics, Heart & Lung, GeriatricsFY26Higher manpower cost, temporary margin impactOperational
Heart & Lung Transplant Centre / KIMS collaboration2025–2026Transplant programme collaboration with KIMS Hospitals, HyderabadOperational
INR 700 Cr fundraiseBoard 2 Feb 2026; shareholders 20 Jul 2026QIP/preferential/private placement; equity, convertibles, NCDs, warrants permittedApproved; execution/pricing not announced as of cut-off
VIMHANS Artemis Hospital MSA20 Feb 202615-year MSA; 650+ beds; capex INR 500–520 Cr (~INR 75–80 lakh per bed); interest-free advance tied to construction milestonesPre-construction; construction expected to begin Apr–May 2026; ~450 beds by FY29
Three-year capex planQ1 FY27 call (Aug 2026)INR 800 Cr covering Gurugram (Tower IV, 200+ beds for paediatrics/obstetrics), Raipur and VIMHANSAnnounced
Additional Gurugram bedsQ4 FY26 call100 beds ready; open 50 when occupancy reaches ~70%, then another 50; expected H2 FY27Pending occupancy trigger
Mauritius CascavelleFY26–FY27Second Mauritius hospital, 110 bedsAnnounced
Investor engagementMar–Sep 2026Hospitals & Diagnostics Conference (23 Mar), hospital visit (19 Jun), PhillipCapital Market Marvel conference (3 Sep)Completed

Medium-term financial targets / guidance

ItemGuidanceSource
Bed capacity2,000–2,300 by 2029Q3/Q4 FY26 calls
FY27 top-line growth (budget)~15%Q4 FY26 call analysis
ARPOB growth7–8% p.a.Q4 FY26 call analysis
International growth FY27"Higher double digits"Q4 FY26 call notes (ValuePickr summary)
Raipur lossesINR 18–20 Cr over first 15–18 monthsQ4 FY26 / Q1 FY27 commentary
Absolute EBITDAContinued expansion in FY27 led by Gurugram occupancy and new bedsQ4 FY26 call notes
CapexINR 800 Cr over three yearsQ1 FY27 commentary
VIMHANS capexPhase 1 ~INR 350 Cr for 450 beds; Phase 2 ~INR 150 Cr for 200 bedsQ4 FY26 call notes

Products & Services

Because AMSL is a hospital operator, its "products" are care formats, facilities and clinical service lines. The catalog below is organised by format, then by clinical programme.

Facilities and care formats

OfferingDescription & capabilitiesTarget customerLaunch / latestPricing model
Artemis Hospital, GurugramFlagship multi-specialty quaternary care campus, Sector 51; JCI & NABH accredited; ~700 beds built across three towers, ~544 operational (Q3 FY26); 100 additional beds ready, to be opened in two lots of 50 once occupancy reaches ~70%Affluent/insured NCR patients, international patients, government-scheme patientsOpened 2007; third tower FY26; Tower IV (200+ beds, paediatrics/obstetrics) plannedFee-for-service; FY26 ARPOB INR 82,435
Artemis Shanti Hospital, Raipur300+ bed multi-specialty tertiary care hospital in Devendra Nagar, Raipur; >50 specialities, 11 Centres of Excellence; cardiology, oncology, neurosciences, orthopaedics, nephrology, critical care, emergency medicineChhattisgarh and Central India patients who would otherwise travel to metrosOPD from 9 Jul 2026; OTs/cath labs from 27 Jul 2026; phased bed opening (reported first phase ~150–200 beds)O&M/MSA; fee-for-service to patients
VIMHANS Artemis Hospital, South Delhi650+ bed multi-specialty hospital to be developed on a 3.5-acre site in Nehru Nagar; ~7 lakh sq ft built-up; CoEs in neurosciences, cardiac sciences, oncology, organ transplantation, critical care and robotic surgerySouth Delhi high-ARPOB micro-marketMSA signed 20 Feb 2026; ~450 beds by FY29 (Phase 1), 650+ in Phase 215-year MSA; land and building owned by VIMHANS society
Artemis Lite30–40 bed neighbourhood multi-specialty hospitals for secondary/tertiary careLocal catchments in South Delhi and New GurugramFirst centre 2023 (South Delhi); New Gurugram unit opened subsequentlyFee-for-service; asset-light
Daffodils by ArtemisMother-and-child care centres (obstetrics, gynaecology, paediatrics, neonatal)Women and children in Gurugram, South Delhi, JaipurGurugram first; Jaipur and South Delhi added 2023Fee-for-service; asset-light
Artemis Cardiac CareCardiac care centres in Tier 2/3 cities via JV with Philips (seven centres cited in 2024)Cardiac patients outside metrosJV incorporated Jan 2019Fee-for-service
Artemis Curepipe Hospital, Mauritius~80-bed hospital operated under O&M agreementMauritian patientsOpened FY24Management fee (terms not disclosed)
Artemis Cascavelle Hospital, Mauritius110-bed facility, second Mauritius hospitalMauritian patientsAnnounced for FY26Management fee (terms not disclosed)

Clinical programmes and centres of excellence (Gurugram unless stated)

ProgrammeDescriptionLatest developmentSource
OncologyMedical, surgical and radiation oncology; high-acuity case mix contributorCore specialtyCARE rationales; company profile
Cardiac sciencesInterventional cardiology, cardiac surgeryHeart & Lung Transplant Centre inaugurated; heart-lung transplant programme in collaboration with KIMS Hospitals, HyderabadMedical Dialogues; ScanX (Jul 2026)
NeurosciencesNeurology, neurosurgery, interventional neuroCore specialtyCompany profile
Orthopaedics & joint replacementIncluding robotic joint replacementCore specialtyCompany profile
Organ transplantationKidney, liver; heart-lung addedHeart-lung programme newSame
Robotic surgeryNew department added FY26 (manpower cost driver)Added FY26Q3 FY26 presentation
GeriatricsNew department added FY26Added FY26Q3 FY26 presentation
Critical careHighlighted on Q4 FY26 call as a success storyOngoingQ4 FY26 call
Nephrology, gastroenterology, minimally invasive surgeryEstablished specialties; no single specialty historically >13% of revenueOngoingCARE rationale 2017
Physiotherapy & sports rehabTechnology-enabled physiotherapy through partnership with Abhinav Bindra Targeting Performance (ABTP)FY25FY25 Directors' Report
OPTIC clinicFirst "OPTIC Clinic" launched (scope not detailed in sources reviewed)2,026Medical Dialogues link reference
Medical value travel deskInternational patient services for 52 countries; Middle East, Africa, CISFY26 overseas revenue INR 322.68 Cr, +26.9%Q4 FY26 release
Digital / patient-flow technologyTechnology deployed to improve patient flow and operational efficiency (details not disclosed)Q3 FY26 callQ3 FY26 transcript

Pricing: management indicated that the FY27 budget assumed price increases of about 15% across domestic and international patients and ARPOB growth of 7–8% annually (Q4 FY26 call analysis, Arthneeti). Procedure-level tariffs are not publicly disclosed.

Financial Narrative

All figures consolidated, INR Cr, fiscal years ending 31 March. Primary anchors: FY26 audited results (8 May 2026) and company press releases. FY22–FY25 line items are taken from StockAnalysis (S&P-sourced, INR millions converted to crore) unless stated, cross-checked against Fyers/Screener totals.

Income statement

Notes: FY26 PAT INR 103.72 Cr (company: +26.2%); PAT attributable to owners INR 103.62 Cr; reported PBT INR 139.18 Cr after an exceptional charge of INR 3.07 Cr (FY26 iXBRL: PBT before exceptional INR 14,225.22 lakh, PBT INR 13,917.78 lakh). FY25 PBT INR 107.67 Cr (Fyers). FY22–FY24 PAT derived from StockAnalysis net margins (5.73%, 5.23%, 5.59%) applied to revenue; FY24 PAT of ~INR 49 Cr is corroborated by Venture Intelligence. "Gross profit" is the aggregator's construct (revenue less cost of revenue including clinical costs) and is not a company-reported metric.

EBITDA (company-reported, INR Cr)

Source: FY26 EBITDA INR 21,801 lakh, +18.0% (Q4 FY26 release); FY25 derived from growth rate.

Per-share data

Notes: EPS shown is a derived approximation; reported basic and diluted EPS differ because of weighted-average share counts and, until conversion, the dilutive IFC CCDs. Reported diluted EPS data points: Q1 FY26 INR 1.54; 9M FY26 INR 4.66 (+21.0%); Q3 FY26 INR 1.41; Q1 FY27 INR 1.98 (+46.7%).

Balance sheet (INR Cr, 31 March)

Source: StockAnalysis balance sheet (INR millions converted). Goodwill & intangibles: not separately disclosed in sources retrieved; hospital operators of this type typically carry minimal goodwill, and no acquisition-related goodwill was identified. Discrepancy note: Arihant Capital's standalone balance sheet shows FY25 total debt of INR 280.5 Cr (secured INR 236.0 Cr plus unsecured INR 44.5 Cr) and cash and bank of INR 393.3 Cr — the large cash figure reflects bank deposits from the IFC proceeds classified outside "cash and equivalents" in the StockAnalysis presentation. On a gross-liquidity basis (including deposits), AMSL was likely net-cash at end-FY25; on the narrow cash definition it shows net debt. Readers should treat "net debt" above as an upper bound.

Cash flow (INR Cr)

Notes and discrepancies: (1) Stockopedia shows FY25 OCF of INR 145.6 Cr versus StockAnalysis INR 155.7 Cr. (3) FY25 debt issuance of INR 350.8 Cr includes the IFC CCDs (INR 330 Cr), which were debt-classified until conversion. Dividends paid: approx. INR 6.2 Cr per year at INR 0.45 on ~137.6 M shares (derived); buybacks: none.

Ratios (derived from tables above; period-end balances)

Additional ratios: Net debt/EBITDA FY25 1.35x and FY26 1.05x (derived; narrow-cash basis). ROIC: not computed due to absence of a reliable tax-adjusted invested-capital series; Screener cites ROCE of 14.9% and ROE of 12.9% (Oct 2026 snapshot) and average 3-year ROE of 11.7%. Cash conversion cycle series is from Screener's standalone data (the last five values in its series are mapped to FY22–FY26; FY26 shown as 37 on one Screener snapshot — minor discrepancy). Fyers shows debt-to-equity of 0.26.

Quarterly trajectory (consolidated, INR Cr)

Sources: Q1 FY27 release (revenue INR 287.32 Cr, EBITDA INR 61.82 Cr, PAT INR 31.44 Cr total / INR 31.31 Cr attributable); Q4 FY26 release (revenue INR 279.23 Cr, EBITDA INR 59.38 Cr, PAT INR 30.28 Cr); Q3 FY26 (revenue INR 272 Cr, EBITDA INR 52 Cr, PAT INR 22.3 Cr); Q1 FY26 from Fyers quarterly series (revenue INR 254.96 Cr; PAT INR 21.28 Cr); Q1 FY26 EBITDA derived from Q1 FY27 growth of 27.9%; Q2 FY26 revenue/EBITDA from Fyers rounded series; Q2 FY26 PAT derived as FY26 PAT less other quarters. Discrepancy: AlphaStreet reported Q1 FY26 revenue as ~INR 250 Cr and INDmoney shows total-income figures (INR 292.70 Cr for Q1 FY27), which include other income.

Commentary on trends, inflections and drivers

Revenue. Growth decelerated sharply from the post-COVID rebound years (36% in FY22, 33% in FY23) to 19% in FY24 and only 6.6% in FY25, before reaccelerating to 15.4% in FY26. The FY25 trough coincided with capacity constraints at the flagship ahead of the third tower and payor-mix noise; the FY26 rebound was driven by ARPOB (+7.8% to INR 82,435 at Gurugram) and a 26.9% jump in overseas-patient revenue. Q1 FY27 growth of 12.7% was achieved despite a sequential softening in international mix (27% vs 31% in Q4 FY26), attributed in part to West Asia geopolitical disruption.

Profitability. Operating margin expanded roughly 470 bps over four years (8.4% to 13.1%), and Q1 FY27 delivered the highest operating margin (ex-other income) in at least eight quarters at 19.6% on an EBITDA-like basis (MarketsMojo). Margin expansion stems from operating leverage on a largely fixed cost base, ARPOB-led pricing and a richer case mix, partially offset in FY26 by manpower additions for robotics, heart-lung and geriatrics. A critical quality-of-earnings point: other income (mainly treasury income on IFC funds) was INR 33.0 Cr in FY25 and INR 29.9 Cr in FY26 (total income minus revenue from ops, derived) — roughly 31% and 21% of PBT respectively — and is declining as funds are deployed (Q1 FY27 other income ~INR 5.4 Cr). Core operating profit, not treasury income, must now carry earnings growth.

Balance sheet. The IFC raise transformed the capital structure in FY25: equity nearly doubled on conversion (INR 448 Cr to INR 838 Cr between FY24 and FY25 on the aggregator's presentation, with share count rising in FY26), debt/equity fell from 0.71x to 0.28x by FY26, and interest coverage improved to 5.8x. Finance costs fell to INR 6.46 Cr in Q1 FY27 from INR 7.38 Cr a year earlier.

Cash flow. FCF has been positive but thin since FY24 (INR 27–63 Cr), as the company continuously reinvests in towers and equipment. The announced INR 800 Cr three-year capex plan (Gurugram Tower IV, Raipur, VIMHANS) will far exceed internal accruals of roughly INR 130–160 Cr per year of OCF, explaining the INR 700 Cr fundraise authorisation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Healthcare Services revenue from operations (INR Cr)

878.6936.91,081.2

YoY growth (%)

19.16.615.4

Share of total revenue (%)

100100100

Revenue by Segment

MetricFY2025FY2026

Standalone AMSL revenue from operations (INR Cr)

913.31,060.5

Subsidiary and consolidation adjustments, derived (INR Cr)

23.620.8

Consolidated revenue from operations (INR Cr)

936.91,081.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Format / Unit Details

Format / unitWhat it containsFY2025 revenue (INR Cr)Notes / source

Artemis Hospital, Gurugram (flagship)

Quaternary/tertiary care, JCI and NABH accredited; ~544 operational beds

Not separately disclosed for full year; FY26 overseas revenue INR 322.68 Cr at 31.3% implies Gurugram net revenue of roughly INR 1,031 Cr (derived)

Q4 FY26 release

Artemis Daffodil

Mother-and-child / women's care units (Gurugram, Jaipur, South Delhi)

21.10

CARE rationale Aug 2025

Artemis Lite

30–40 bed neighbourhood multi-specialty hospitals (South Delhi, New Gurugram)

19.60

CARE rationale Aug 2025

Artemis Cardiac Care Pvt Ltd

Cardiac centres in Tier 2/3 cities with Philips (7 centres per 2024 release)

Subsidiary revenue not separately disclosed; subsidiary Q1 FY27 net profit INR 0.38 Cr; total assets INR 22.60 Cr

Q1 FY27 results notes

Mauritius O&M

Artemis Curepipe (~80 beds), Artemis Cascavelle (110 beds)

—

Presentations

Raipur (Artemis Shanti)

300+ bed super-speciality hospital under O&M/MSA

Nil (commenced Jul 2026)

Reg. 30 disclosure

VIMHANS Artemis Hospital

650+ bed hospital under 15-year MSA

Nil (targeted FY29)

Reg. 30 disclosure

Artemis Solace

Named as a diversified care model by AlphaStreet; scope not detailed in primary sources reviewed

—

AlphaStreet, Q1 FY26 note

“—” = not publicly disclosed.

Segment Revenue

MetricQ4 FY25Q4 FY26Q1 FY26 (derived)Q1 FY27

Revenue from operations

225.1 (derived)

267.5241.3278.5

EBITDA

48.158.049.561.6

PAT

26.2 (derived)

31.424.933.1

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

554.8737.4878.6936.91,081.2

Total income incl. other income (INR Cr)

558.7744.8885.9969.91,111.1

Gross profit, aggregator definition (INR Cr)

91.9138.1177.6197.7237.7

Operating income / EBIT before other income (INR Cr)

46.563.993.5108.1142.1

Interest expense (INR Cr)

9.417.327.828.524.5

Pre-tax income excl. unusual items (INR Cr)

37.749.568.2105.5141.0

Net income / PAT (INR Cr)

31.838.649.182.6103.7

Revenue growth (%)

35.932.919.16.615.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2025–FY2026)

MetricFY2025FY2026

Consolidated EBITDA (INR Cr)

184.8218.0

EBITDA margin (%)

19.720.2

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin, aggregator basis (%)

16.618.720.221.122.0

Operating margin (%)

8.48.710.611.513.1

Net margin on revenue from ops (%)

5.75.25.68.89.6

Share Count (millions) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Shares outstanding, period-end (millions)

132.4134.1135.9137.6158.3

EPS approx., PAT / period-end shares (INR)

2.402.883.616.006.55

Valuation Snapshot

MetricValueBasis

Revenue CAGR FY2022–FY2026 (4-year)

18.2%

Derived from INR 554.8 Cr to INR 1,081.2 Cr

Revenue CAGR FY2023–FY2026 (3-year)

13.6%

Derived

PAT CAGR FY2022–FY2026

34.4%

Derived from INR 31.8 Cr to INR 103.7 Cr

Screener: 5-year profit CAGR

32.5%

Screener, Oct 2026

Last verified price

INR ~311 (NSE)

12 Oct 2026, Kotak Neo / Tickertape

Market cap

~INR 4,958 Cr

12 Oct 2026

52-week high / low

INR 378.80 / INR 203.35

Kotak Neo, 12 Oct 2026 (Anand Rathi in mid-Sep showed INR 361.50 / INR 202.85 — discrepancy)

1-year return

~30.0%

Kotak Neo, 12 Oct 2026

3-year return

~150%

Anand Rathi, Sep 2026

Recent price points

INR 274.6 (29 May 2026); INR 259.2 (18 Jun 2026); INR 298.5 (31 Jul 2026); INR 316.9 (10 Aug 2026); INR 326.1 (22 Aug 2026); INR 337.5 (15 Sep 2026); INR 311 (12 Oct 2026)

Various aggregators

Metric

May2026

Jun2026

Share price, sampled close (INR)

274.6259.2

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

709.7905.0971.51,357.41,428.7

Cash and equivalents (INR Cr)

15.722.914.641.633.4

Cash plus short-term investments (INR Cr)

27.750.914.641.633.4

Current portion of long-term debt (INR Cr)

22.327.925.836.336.9

Long-term debt (INR Cr)

161.3213.6227.7209.5190.0

Total debt incl. leases (INR Cr)

201.2285.9320.3290.3261.6

Net debt (INR Cr)

173.5234.9305.7248.7228.2

Total equity (INR Cr)

359.4403.1448.4837.7934.7

Total current assets (INR Cr)

127.0170.4180.1535.1366.8

Total current liabilities (INR Cr)

138.2205.8184.6216.1210.8

Working capital, derived (INR Cr)

-11.2-35.4-4.5319.0156.0

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

59.5127.2108.9155.7131.9

Capital expenditure, derived (INR Cr)

108.9146.572.693.1104.9

Free cash flow (INR Cr)

-49.4-19.336.362.627.0

Investing cash flow (INR Cr)

-107.2-158.2-88.1-393.2-90.0

Financing cash flow (INR Cr)

44.238.2-29.0264.5-50.1

Long-term debt issued (INR Cr)

79.182.845.3350.864.2

Long-term debt repaid (INR Cr)

24.627.537.240.380.9

Cash interest paid (INR Cr)

11.120.133.031.127.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE, period-end equity (%)

8.89.611.09.911.1

ROA, period-end assets (%)

4.54.35.16.17.3

Current ratio (x)

0.920.830.982.481.74

Debt to equity (x)

0.560.710.710.350.28

Interest coverage, EBIT / interest (x)

4.973.703.373.795.81

Asset turnover, revenue / assets (x)

0.780.810.900.690.76

Cash conversion cycle (days)

5048474336

Income Statement

MetricQ1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue from operations (INR Cr)

255.0275.0272.0279.2287.3

EBITDA (INR Cr)

48.358.052.059.461.8

PAT (INR Cr)

21.329.822.330.331.3

Revenue by Region and Revenue by Region (%)

MetricFY2025FY2026

Overseas-patient revenue, Gurugram (INR Cr)

254.3322.7

Domestic revenue, consolidated less overseas, derived (INR Cr)

682.6758.6

Overseas share of Gurugram net revenue (%)

28.031.3

Overseas revenue growth (%)

026.9

Revenue by Region (%) and Region Margins & Growth (%)

MetricQ3FY2026Q4FY2026Q1FY2027

Overseas share of revenue (%)

34.030.827.5

Overseas revenue YoY growth (%)

34.913.58.6

Geography Overview

GeographyRoleDisclosure

India — Delhi-NCR (Gurugram, South Delhi)

Core; flagship, Lite, Daffodils, future VIMHANS

~95%+ of revenue (derived from entity split)

India — Rajasthan (Jaipur)

Daffodils unit

—

India — Chhattisgarh (Raipur)

New tertiary hospital from Jul 2026

No revenue in FY26

India — Tier 2/3 cities

Artemis Cardiac Care centres

Subsidiary revenue small (consolidation residual ~INR 21 Cr FY26)

Mauritius

O&M of Curepipe and Cascavelle hospitals

—

International patient source markets

Middle East, Africa, CIS (52 countries)

Country-level split not disclosed

“—” = not publicly disclosed.

Valuation Multiples

MultipleArtemisBasis

P/E (TTM)

43.6x

Mcap INR 4,958 Cr / TTM PAT INR 113.7 Cr (FY26 PAT – Q1 FY26 + Q1 FY27)

EV/EBITDA (TTM)

22.4x

EV INR 5,186 Cr (mcap + Mar-26 net debt INR 228 Cr) / TTM EBITDA INR 231.5 Cr

EV/Sales (TTM)

4.7x

EV / TTM revenue INR 1,113.5 Cr

P/B

5.3x

Mcap / Mar-26 equity INR 934.7 Cr (aggregators show 3.2x–5.0x depending on date and book definition)

Dividend yield

~0.15%

INR 0.45 / INR 311

Dividend History

Fiscal yearDPS (INR)Record / ex-dateStatus

FY2024

0.45

Ex-date 5 Jul 2024

Verified

FY2026

0.45

Record date 10 Jul 2026; approved at AGM 31 Jul 2026

Verified

Credit Ratings

AgencyRatingOutlookDate

CARE Ratings — long-term bank facilities (INR 427.90 Cr)

CARE A

Stable

Reaffirmed 12 Aug 2025

CARE Ratings — long/short-term facilities (INR 45 Cr)

CARE A / CARE A2+

Stable

Reaffirmed 12 Aug 2025

Moody's / S&P / Fitch

Not rated

——

Analyst Conclusions

Management guidance (FY27 and beyond)

Management has framed FY27 around ~15% top-line growth, 7–8% ARPOB growth, continued absolute EBITDA expansion at Gurugram, phased opening of 100 additional Gurugram beds once occupancy approaches 70%, and Raipur gestation losses of INR 18–20 Cr over 15–18 months. Longer term, it targets 2,000–2,300 beds by 2029 backed by an INR 800 Cr three-year capex plan and an INR 700 Cr equity raise. Consensus growth expectations: not publicly disclosed in sources reviewed.

Bull case

  1. Core flagship compounding: Gurugram delivered +15.4% revenue and +24.4% EBITDA in Q1 FY27 with occupancy at 65.7%; crossing ~70% unlocks 100 ready beds at minimal incremental capex, extending double-digit growth into FY28.

  2. Capacity optionality at low capital intensity: VIMHANS (~INR 75–80 lakh per bed under an MSA) and Raipur (O&M) add roughly 950 beds without full land/building ownership, which could lift ROCE once ramped.

  3. Valuation gap: at ~44x TTM earnings and ~22x EV/EBITDA, Artemis trades below most large NCR peers despite comparable ARPOB; successful execution and the equity raise could drive a rerating toward peer multiples.

Bear case

  1. Earnings quality and dilution: treasury income (~21% of FY26 PBT) is fading, Raipur losses will weigh on FY27–FY28, and a full INR 700 Cr raise at current prices implies ~14% dilution — EPS growth could lag headline PAT growth.

  2. MVT and competitive headwinds: international share has already slid from 34% to 27% in three quarters; peers are adding thousands of NCR beds, potentially capping occupancy and pricing.

  3. Execution and governance overhangs: an MSA-heavy pipeline with interest-free advances, a 44.5% promoter pledge, a single-asset earnings base, and an FY29 timeline for VIMHANS leave limited margin for delay.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q2 FY27 resultsLikely early-to-mid Nov 2026 (unconfirmed)First quarter with Raipur losses; Gurugram occupancy vs 70% trigger
INR 700 Cr fundraise executionH2 FY27 (unconfirmed)Pricing, dilution, investor quality
Opening of additional 100 Gurugram bedsH2 FY27Occupancy trigger
Raipur rampThrough FY27Bed occupancy, breakeven trajectory vs INR 18–20 Cr loss guidance
VIMHANS construction progressFY27–FY29Milestones, advances paid
International patient trendsQuarterlyShare vs 30% target; West Asia situation
CGST SCN outcomeFY27Settlement or litigation
Board refreshFY27Replacement of independent director(s)
CARE rating review~Aug 2027Possible upgrade/downgrade given capex

Analyst verdict

Artemis Medicare enters FY27 in the best operating shape of its 19-year history. The Gurugram flagship is delivering record revenue, NCR-leading ARPOB above INR 85,000, and an EBITDA margin that has broken above 20%, while the IFC capital infusion has cut leverage to a debt-to-equity ratio below 0.3x. FY26 PAT grew 26% and Q1 FY27 PAT grew 48% — numbers that compare favourably with the much larger listed hospital chains.

The investment debate, however, has shifted from "is the flagship good?" to "can a one-hospital company become a four-hospital company without diluting returns?" The answer will be determined over the next 24–36 months by three variables: how quickly Raipur fills its beds in a market with entrenched competitors; whether VIMHANS is delivered on its FY29 timeline and on budget; and whether the INR 700 Cr equity raise is priced well enough that per-share value accretes. Meanwhile, the earnings cushion from treasury income is disappearing, and international patient flows — the core of the premium-yield story — have shown that they are sensitive to geopolitical shocks.

On balance, the evidence supports a constructive but execution-dependent view. The core asset justifies a premium franchise multiple, and the current valuation (~44x TTM P/E, ~22x EV/EBITDA) embeds a discount to large peers that reflects scale and concentration risk rather than core quality. Upside requires Gurugram occupancy to break 70% and Raipur losses to stay within guidance; downside scenarios centre on slower MVT, a heavily dilutive raise, or construction slippage at VIMHANS. Investors should treat the next four quarterly prints — particularly occupancy, Raipur losses and the fundraise terms — as the decisive evidence on whether Artemis can translate its high-quality flagship into a scaled, returns-accretive platform.


Source list (primary and secondary references used)

SourceTypeUsed for
NSE iXBRL integrated filings — FY26 audited results (8 May 2026); Q2 FY26 results (11 Nov 2025)Primary filingRevenue, PBT, PAT, segment, subsidiary
Q3 & 9M FY26 earnings presentation (2 Feb 2026) and call transcript (3 Feb 2026, filed 9 Feb 2026)PrimaryARPOB, MVT, capacity, CFO name
Reg. 30 disclosure — VIMHANS MSA (20 Feb 2026)PrimaryVIMHANS terms
Reg. 30 disclosure — auditor re-appointment (31 Jul 2026)PrimaryAuditor
Reg. 30 disclosure — SMP appointment (18 Sep 2025)PrimaryManagement
Company press releases via Indian Pharma Post / Equitybulls (Q4 FY26, Q1 FY27, VIMHANS)Primary (reproduced)KPIs, quotes
IFC project disclosure 49344Primary (counterparty)IFC investment
CARE Ratings press releases (2015–2025)Rating agencyRatings, history, format revenue
Business Standard (ICRA bed estimates)MediaIndustry context
ScanX, Sahi, MultiBagg, MarketsMojo, Medical Dialogues, AlphaStreetMedia / aggregatorsNewsflow, Raipur, fundraise
StockAnalysis, Screener, Fyers, Kotak Neo, Tickertape, Anand Rathi, Angel One, IIFL, Emkay, Arihant, Stockopedia, Simply Wall St, Pocketful, VoguestockAggregators5-year financials, market data, shareholding, compensation
PTL Enterprises and Artemis Global Life Sciences filings (2015–2019)Primary (historic)Corporate history

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (latest available)Source

Dr. Devlina Chakravarty

Managing Director (Executive Director)

Joined as CEO Jan 2014; MD since 2 Feb 2015

Medical doctor (MD, DNB, DMRD — radiology); long-serving operator of the flagship

—

Simply Wall St

Sanjiv Kumar Kothari

Chief Financial Officer

———

Q3 FY26 transcript

Poonam Makkar

Company Secretary & Compliance Officer (KMP)

Since 9 Nov 2022

Member, Institute of Company Secretaries of India

~INR 0.42 Cr (S&P-sourced data)

Board outcome Nov 2022; Simply Wall St

Rudra Narayan Acharjee

Head – Investor Relations, M&A and Organisation Growth Strategy (SMP)

Since 18 Sep 2025

Not detailed in sources reviewed

—

Reg. 30 disclosure

“—” = not publicly disclosed.

Board of Directors

NameRoleNotesSource

Onkar S. Kanwar

Chairman (Non-Executive, Promoter)

Chairman of Apollo Tyres Ltd

Company releases 2024–2026

Neeraj Kanwar

Non-Executive Director (Promoter group)

Vice Chairman & MD of Apollo Tyres; retired by rotation and re-appointed at 21st AGM (2025)

FY25 Directors' Report

Shalini Kanwar Chand

Non-Executive Director (Promoter group)

—

MarketsMojo management list (Mar 2023)

Dr. Devlina Chakravarty

Managing Director

Executive

Same

Deepa Gopalan Wadhwa

Independent Director

Former Indian diplomat (Ambassador) — background per public record

Same

Sunil Tandon

Independent Director

—

Same

S. Narayan

Independent Director

Former Finance Secretary, Government of India — per public record

Same

Dr. Nirmal Kumar Ganguly

Independent Director

Former Director-General, ICMR — per public record

Same

Dr. Sanjaya Baru

Independent Director

Economist and former media adviser to the Prime Minister — per public record

Same

Sanjib Sen

Independent Director (ceased)

Second term 3 Aug 2023 – 2 Aug 2026; ceased on completion of tenure

FY24 Directors' Report; Reg. 30 disclosure Aug 2026

Major Shareholders

HolderStake (%)As ofSource

Constructive Finance Private Limited (promoter holding company)

58.38

Jun 2026

MarketsMojo shareholding

Onkar Kanwar (individual promoter)

0.01

Mar 2026

Shareholding pattern

Total promoter & promoter group

58.39

Jun 2026

Exchange filing

International Finance Corporation (IFC)

11.98

Jun 2026

MarketsMojo

Total FIIs (21 FIIs, incl. IFC)

12.29

Jun 2026

MarketsMojo

Body corporate where Central/State Govt is promoter (name not disclosed in excerpt)

1.90

Mar 2026

Shareholding pattern

Mutual funds (5 schemes)

1.30

Jun 2026

MarketsMojo

Unclaimed suspense account

1.48

Mar 2026

Shareholding pattern

Individual investors

12.79

Jun 2026

MarketsMojo

Promoter shares pledged / encumbered

44.53% of promoter holding

Jun 2026

MarketsMojo; Screener

Competitive Landscape

Key Competitors

CompetitorOverlap with ArtemisRelative positioning

Medanta (Global Health Ltd)

Gurugram quaternary care — the most direct head-to-head competitor, located in the same city

Much larger; strong transplant/cardiac brand

Fortis Healthcare (FMRI Gurugram, Fortis Escorts, Shalimar Bagh, Vasant Kunj etc.)

Gurugram and South/West Delhi high-acuity care; MVT

Larger network; FMRI is a direct Gurugram rival

Max Healthcare Institute (Saket, Patparganj, Shalimar Bagh, Gurugram)

South Delhi (Saket) — key rival for VIMHANS catchment; MVT

Market leader in NCR by beds and ARPOB

Apollo Hospitals Enterprise (Indraprastha Apollo, Sarita Vihar)

South Delhi tertiary care; MVT

National leader

Manipal Hospitals (Dwarka, Gurugram)

West Delhi/Gurugram tertiary care

Large private network

Paras Health (Gurugram)

Gurugram multi-specialty

Mid-sized regional player

Narayana Health (Gurugram, Raipur MMI Narayana)

Gurugram presence and Raipur (MMI Narayana) — direct competitor for Artemis Shanti

Strong in Central/East India

Ramkrishna CARE Hospitals / other Raipur tertiary hospitals; AIIMS Raipur (public)

Raipur catchment

Incumbents in Chhattisgarh

Sir Ganga Ram, Indian Spinal Injuries Centre, BLK-Max

Delhi tertiary trust/private hospitals

Strong legacy brands

Aster DM Healthcare, KIMS (Krishna Institute of Medical Sciences)

Capital-market peers; KIMS also collaborator

Listed peer benchmarks

Peer Comparison FY2026

CompanyMarket cap (INR Cr)P/E (x)Source / caveat

Artemis Medicare

4,95843.6

Mcap 12 Oct 2026 (Kotak Neo); P/E derived on TTM PAT INR 113.7 Cr

Apollo Hospitals

126,30060.5

Fyers peer table, date not stated

Max Healthcare

96,76366.4

Same

Manipal Hospitals

95,496107.0

Same

Fortis Healthcare

68,90165.8

Same

Aster DM Healthcare

68,592215.2

Same

Narayana Health

38,43947.1

Same

Medanta (Global Health)

38,14968.6

Same

Recent Developments

Next expected event: board meeting to approve Q2 FY27 (quarter ended 30 Sep 2026) results — date not announced as of cut-off; prior-year Q2 was approved on 11 Nov 2025.

Company Snapshot

$124.8M

Revenue

2004

Founded

Gurugram, India

Headquarters

SWOT Analysis

Strengths

  • Premium pricing power: Gurugram ARPOB INR 82,435 in FY26 (+7.8%) and INR 85,690 in Q1 FY27 (+7.4%) — Q4 FY26 and Q1 FY27 releases
  • Accelerating profitability: FY26 PAT +26.2% to INR 103.7 Cr; Q1 FY27 PAT +48.3%; operating margin rose from 8.4% (FY22) to 13.1% (FY26)
  • Strong MVT franchise: Overseas revenue INR 322.7 Cr in FY26, +26.9%, 31.3% of Gurugram revenue; 52 source countries
  • De-levered balance sheet: Debt/equity fell from 0.71x (FY24) to 0.28x (FY26); interest coverage 5.8x; finance cost down to INR 6.46 Cr in Q1 FY27
  • Credible institutional backing: IFC INR 330 Cr investment (11.98% stake); Apollo Tyres promoter group (58.39%)
  • Investment-grade credit: CARE A; Stable / A2+ reaffirmed Aug 2025 (upgraded from A-)
  • Quality accreditations: JCI and NABH accreditation of flagship
  • Shareholder support for growth capital: 98.68% approval of INR 700 Cr fundraise (20 Jul 2026)

Weaknesses

  • Single-asset concentration: Standalone revenue INR 1,060 Cr of INR 1,081 Cr consolidated in FY26; Gurugram dominates
  • Sub-par returns: Screener 3-year average ROE 11.7%; period-end ROE 11.1% in FY26
  • Thin free cash flow: FCF INR 27 Cr in FY26 (2.5% margin) per StockAnalysis series
  • Reliance on treasury income: Other income ~INR 30–33 Cr in FY25–FY26, ~21–31% of PBT, now declining as IFC funds are deployed
  • Moderate occupancy: Gurugram occupancy 61–66% over FY26–Q1 FY27; 100 ready beds held back until ~70%
  • Promoter pledge: 44.53% of promoter holding pledged/encumbered (Jun 2026)
  • Small scale vs. peers: Market cap ~INR 5,000 Cr vs. INR 38,000–126,000 Cr for listed peers

Opportunities

  • Capacity tripling: 2,000–2,300 beds targeted by 2029 from ~800
  • South Delhi entry: VIMHANS 650+ bed MSA; ~450 beds by FY29; capex ~INR 75–80 lakh per bed
  • Brownfield Gurugram: 100 beds ready; Tower IV adds 200+ beds; 15% FAR uplift secured
  • Tier 2 expansion: Raipur 300+ beds opened Jul 2026; model replicable
  • New high-acuity programmes: Heart-lung transplant, robotics, geriatrics launched FY26
  • Insurance penetration: Insured share up to 33% in Q1 FY27
  • Rerating on execution: P/E ~44x vs. 47–107x for most large listed peers (Fyers snapshot)

Threats

  • Geopolitical MVT disruption: International share fell from 34% (Q3 FY26) to 27% (Q1 FY27); March 2026 dip linked to West Asia conflict
  • NCR bed glut: ICRA: 34,000+ private beds to be added nationally by FY29; peers expanding in NCR
  • Gestation losses: Raipur losses guided at INR 18–20 Cr over 15–18 months
  • Equity dilution: Up to INR 700 Cr raise ≈ 14% of current market cap
  • Tax and labour disputes: CGST SCN of INR 11.11 Cr plus interest/penalty (Sep 2026); PF writ (resolved favourably)
  • Execution risk on MSAs: VIMHANS construction started only in 2026 with FY29 target; interest-free advances at risk if counterparty underperforms

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025FY25 results; FY25 consolidated revenue INR 936.9 Cr, PAT ~INR 82.6 Cr Fyers; FY26 comparativesBase year for FY26 growth
Jul–Aug 2025Q1 FY26 results: revenue ~INR 255 Cr (+15%), PAT INR 21.3 Cr (+24%), EPS INR 1.54 AlphaStreet; FyersSolid start to FY26
12 Aug 2025CARE reaffirms CARE A; Stable / A2+; LT bank facilities enhanced to INR 427.90 Cr; notes VIMHANS arrangement and FY25 Daffodil (INR 21.1 Cr) and Lite (INR 19.6 Cr) revenue CARE RatingsInvestment-grade bank credit maintained
18 Sep 2025Rudra Narayan Acharjee appointed Head – IR, M&A and Growth Strategy Reg. 30Signals inorganic/expansion intent
Oct 2025Trading window closed for Q2 FY26 results WhalesbookProcedural
11 Nov 2025Q2 FY26 results: revenue +15%, PAT +33–36% NSE iXBRL; WhalesbookStrong margin delivery
Q3 FY26Monitoring agency report shows only INR 0.33 Cr utilised from INR 330 Cr preferential issue in the quarter (for stamp duty) ScanXIndicates IFC funds largely parked in treasury pending capex
Q3 FY26Platinum green building certification enabling 15% FAR uplift Q3 FY26 presentationUnlocks 100+ beds at Gurugram
FY26Allotment of ~1.06 lakh ESOP shares WhalesbookMinor dilution
2 Feb 2026Q3 FY26 results: revenue INR 272 Cr (+17.2%), EBITDA INR 52 Cr, PAT INR 22.3 Cr (+7.9%); board approves up to INR 700 Cr fundraise Board outcome; ScanXProfit growth slowed by new-department costs; capital plan launched
3 Feb 2026Q3 FY26 earnings call: international revenue +34.9% (34% of revenue); ARPOB INR 84,100 (+10%); 2,000+ bed ambition reiterated TranscriptStrong MVT momentum
20 Feb 2026MSA for 650+ bed VIMHANS Artemis Hospital, South Delhi Reg. 30Largest single capacity addition in company history
Feb–Mar 2026Delhi High Court dismisses a writ petition filed by the Regional PF Commissioner, Gurgaon WhalesbookFavourable legal outcome (details not disclosed)
Mar 2026IFC CCD conversion reflected in shareholding: promoter at 58.39%, IFC 11.98% Shareholding patternFree float and institutional ownership increase
23 Mar 2026Participation in Hospitals & Diagnostics Conference, Mumbai ScanXInvestor outreach
Mar 2026International patient inflows dip amid West Asia conflict Q4 FY26 call notesHighlights geopolitical sensitivity of MVT
8 May 2026FY26 audited results: revenue INR 1,081 Cr (+15.4%), EBITDA INR 218 Cr (+18%), PAT INR 103.7 Cr (+26.2%); Q4 PAT +32.1%; final dividend INR 0.45 recommended Q4 FY26 release; iXBRLRecord year
May 2026Q4 FY26 call: Raipur on track for Q1 FY27; INR 18–20 Cr gestation losses; 100 Gurugram beds ready Call summariesGuidance framework for FY27
1–4 Jun 2026Board meets to approve postal-ballot notice for INR 700 Cr raise ScanXProcess step
3 Jun 2026Raipur hospital launch publicised: 300+ beds, >50 specialities, 11 CoEs Medical DialoguesBrand launch in Chhattisgarh
18–19 Jun 2026Board approves fundraise resolution; investor hospital visit at Gurugram (19 Jun) Sahi; ScanXEngagement ahead of raise
7 Jul 2026BRSR FY2025-26 filed ScanXESG disclosure
9 Jul 2026Artemis Shanti Hospital, Raipur commences operations (OPD) Reg. 30First hospital outside NCR in India
10 Jul 2026Record date for INR 0.45 final dividend Exchange filingShareholder return
20 Jul 2026Postal ballot result: INR 700 Cr fundraise approved with 98.68% support Scrutiniser's reportRemoves corporate approval hurdle
27 Jul 2026Raipur operating theatres and cath labs activated Q1 FY27 commentaryEnables surgical/IP ramp
31 Jul 202622nd AGM: dividend approved; T R Chadha & Co LLP re-appointed as auditor to 2031 Reg. 30Governance continuity
2 Aug 2026Independent Director Sanjib Sen's tenure ends Reg. 30Board refresh needed
3 Aug 2026Q1 FY27 results: revenue INR 287.3 Cr (+12.7%), EBITDA INR 61.8 Cr (+27.9%), PAT INR 31.4 Cr (+48.3%); occupancy 65.7%; ARPOB INR 85,690 Q1 FY27 releaseRecord quarter, margin inflection
4 Aug 2026Q1 FY27 earnings call; INR 800 Cr three-year capex plan; Tower IV (200+ beds) for paediatrics/obstetrics Call summariesCapex visibility
10 Aug 2026Q1 FY27 call transcript filed SharekhanDisclosure
3 Sep 2026Investor conference (PhillipCapital Market Marvel, Delhi) Reg. 30Pre-raise marketing
28–29 Sep 2026Trading window closure from 1 Oct 2026; CGST Gurugram show-cause notice for FY23 — INR 11.11 Cr plus interest and penalty Screener announcementsIndirect-tax contingency
6 Oct 2026Reg. 74(5) compliance certificate for quarter ended 30 Sep 2026 ScreenerProcedural
12 Oct 2026Shares at ~INR 311; market cap ~INR 4,958 Cr Kotak NeoMarket context

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment (FY2024–FY2026): Healthcare Services revenue from operations rose from INR 8,786 Mn in FY2024 to INR 10,812 Mn in FY2026.
Artemis Medicare Services Limi — Revenue by Segment (FY2024–FY2026)
Series (INR Mn)FY2024FY2025FY2026
Healthcare Services revenue from operations8,7869,36910,812

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.